Registry for patients with adrenocortical carcinoma in Germany

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The German Adrenocortical Carcinoma Registry aims to enhance the care of patients diagnosed with adrenocortical cancer by collecting extensive data on treatment outcomes and prognoses. By registering as many patients as possible, the study facilitates the planning of future prospective studies and improves recruitment for these studies. The registry also aims to collaborate with international networks to systematically enhance treatment strategies for this rare cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed diagnosis of adrenocortical carcinoma

Where it's running

• University of Wuerzburg
  Würzburg, Germany Recruiting

Study contacts

• Principal investigator: Martin Fassnacht, MD — University of Wuerzburg
• Study coordinator: Martin Fassnacht, MD
• Email: fassnacht_m@medizin.uni-wuerzburg.de
• Phone: 49-931-201-36507

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining PD-1 antibody with radiotherapy for advanced adrenal cancer

  This study is testing if a new treatment that combines a PD-1 antibody with radiotherapy can help adults with advanced adrenal cancer who haven't had success with other treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06587802

• Dostarlimab treatment for advanced or metastatic cancers with specific genetic markers

  This study is testing if the immunotherapy dostarlimab can help people with certain advanced cancers that have specific genetic markers feel better compared to standard chemotherapy.

  Recruiting Phase 2 Unicancer · Angers and 21 other locations · NCT06333314

• Combining radiotherapy with pembrolizumab for advanced adrenocortical carcinoma

  This study is testing if giving pembrolizumab after radiation therapy can help people with advanced adrenocortical carcinoma feel better and manage their symptoms.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06066333

• Adding progesterone to standard chemotherapy for advanced adrenocortical carcinoma

  This study is testing if adding a form of progesterone to standard chemotherapy can help people with advanced adrenocortical carcinoma feel better and improve their treatment results.

  Recruiting Phase 2 Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Brescia · NCT05913427

• Gene modified immune cells for treating advanced melanoma and metastatic solid tumors

  This study is testing if modified immune cells can safely target and attack advanced melanoma and other solid tumors in patients after they receive chemotherapy.

  Recruiting at 3 sites Phase 1 Stanford University · Duarte, California and 2 other locations · NCT04119024

• Investigating genetic factors in childhood cancer

  This study is trying to find out if certain genes passed down in families can increase the risk of childhood cancer by looking at samples from kids who have had cancer and their relatives.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT03050268

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.